Key result
Antiplatelet therapy in hemodialysis patients was associated with a significantly higher rate of bleeding events compared to no antiplatelet therapy (40.4% vs 11.9%; P<0.001).
Why the study?
Does antiplatelet therapy increase bleeding events in hemodialysis patients?
Population
111 hemodialysis patients treated in a single clinic
Comparison
Antiplatelet therapy vs No antiplatelet therapy
Design
Cohort
Follow-up
1073±696 days and 917±605 days
Authors
Loading...
May warrant caution with antiplatelet therapy in hemodialysis; leaves open randomized confirmation of net clinical benefit.
Cohort (n=111)
No
Does antiplatelet therapy increase bleeding events in hemodialysis patients?
Absolute Event Rate: 40.4% vs 11.9%
p-value: p=<0.001
Antiplatelet therapy significantly increases the risk of bleeding events requiring heparin cessation in hemodialysis patients, particularly those with diabetes.
Daimon et al. (2011) conducted a cohort in Hemodialysis (n=111). Antiplatelet medications vs. No antiplatelet medications was evaluated on Bleeding events that required the cessation of the use of heparin for hemodialysis (p=<0.001). Antiplatelet therapy in hemodialysis patients was associated with a significantly higher rate of bleeding events compared to no antiplatelet therapy (40.4% vs 11.9%; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: